首页>投融资
Complement Therapeutics
A轮
Complement Therapeutics is a spin-out from the University of Manchester, focused on the research and development of novel therapeutic approaches to address unmet needs in diseases related to complement dysregulation.In April 2023, Complement Therapeutics GmbH completed a €72 million Series A financing.In February 2022, Complement Therapeutics Ltd announced the completion of its EUR 5 million seed financing round from BioGeneration Ventures (BGV) and Forbion
基本信息
-
公司全称Complement Therapeutics Ltd
-
类型药物开发商
-
产业领域药品研发/制造
-
公司人数15人以下
-
地址4th Floor,Central Working White City LONDON WC2A; GB;
-
联系电话
-
邮箱info@complementtx.com
-
成立时间2020-01-01
投融资
-
2023-04-17A轮7200万欧元GimvForbion Capital PartnersPanakes PartnersSeroba Life SciencesBioGeneration VenturesCambridge Innovation Capital plcHadean Ventures
-
2023-04-17A轮7200万欧元Cambridge Innovation Capital plcGimvSeroba Life SciencesBioGeneration VenturesHadean VenturesForbion Capital PartnersPanakes Partners
-
2022-02-23种子轮500万欧元BioGeneration VenturesForbion Capital Partners
-
2022-02-23种子轮500万欧元BioGeneration VenturesForbion Capital Partners
- 加载更多
相关投融资企业
PreA轮
Epitopea Ltd develops cancer immunotherapies intended to offer therapeutics targeting a novel class of tumour-specific antigen. The company's technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, curing cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.In May 2022, Novateur Ventures had participated in the $13.6M (£10.3M) seed investment raised by Epitopea Ltd.In April 2022, Epitopea had announced a $13.6M seed investment from Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ
C轮
Alpha-9 Oncology 是一家处于临床阶段的放射性药物公司，致力于开发差异化和高度靶向性的放射性药物，有望显著改善癌症患者的治疗。Alpha-9 运用专有技术和深厚的基础专业知识，走在定制放射性药物工程的前沿，这些药物经过优化，可选择性地向肿瘤部位输送射线，同时最大限度地减少脱靶效应。Alpha-9 正在推进一个强大的新型放射性药物管线，该管线采用系统化的分子设计方法，具有向多个有效肿瘤靶点扩展的广泛潜力。
A轮
March Biosciences是一家临床阶段生物技术公司。该公司致力于治疗对现有免疫疗法无反应的挑战性癌症。其主要资产MB-105是一种以CD5为靶点的嵌合抗原受体T细胞（“CAR-T”）疗法，CD5是一个在正常和恶性T细胞（包括T细胞相关的白血病和淋巴瘤）中广泛表达的蛋白质。这限制了其作为癌症治疗靶点的用途，因为正常免疫系统功能所需的健康T细胞将与恶性T细胞一起被破坏。MB-105经过特别设计，既能保留健康的T细胞，又能保持对CD5阳性肿瘤细胞的杀伤力。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息